Prostate Cancer Biomarker Module

CME

Biomarker Testing in Prostate Cancer: An Essential Component in Transforming Care

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 22, 2024

Expiration: March 21, 2025

Himisha Beltran
Himisha Beltran, MD
Steven Christopher Smith
Steven Christopher Smith, MD, PhD

Activity

Progress
1 2
Course Completed

References

  1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12-49.
  2. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: prostate cancer. seer.cancer.gov/statfacts/html/prost.html. Accessed March 19, 2024.
  3. Simon NI, Parker C, Hope TA, et al. Best approaches and updates for prostate cancer biochemical recurrence. Am Soc Clin Oncol Educ Book. 2022;42:1-8.
  4. National Cancer Institute. Prostate cancer treatment (PDQ®)–health professional version. cancer.gov/types/prostate/hp/prostate-treatment-pdq. Accessed March 19, 2024.
  5. Sandhu S, Moore CM, Chiong E, et al. Prostate cancer. Lancet. 2021;398:1075-1090.
  6. Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015;10:e0139440.
  7. Zhang W, van Gent DC, Incrocci L, et al. Role of the DNA damage response in prostate cancer formation, progression and treatment. Prostate Cancer Prostatic Dis. 2020;23:24-37.
  8. Burdak-Rothkamm S, Mansour WY, Rothkamm K. DNA damage repair deficiency in prostate cancer. Trends Cancer. 2020;6:974-984.
  9. Dhawan M, Ryan CJ, Ashworth A. DNA repair deficiency is common in advanced prostate cancer: new therapeutic opportunities. Oncologist. 2016;21:940-945.
  10. Georgiou D, Monje-Garcia L, Miles T, et al. A focused clinical review of Lynch Syndrome. Cancer Manag Res. 2023;15:67-85.
  11. Maiorano BA, Conteduca V, Catalano M, et al. Personalized medicine for metastatic prostate cancer: the paradigm of PARP inhibitors. Crit Rev Oncol Hematol. 2023;192:104157.
  12. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26:3785-3790.
  13. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16:110-120.
  14. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355;1152-1158.
  15. Jalal S, Earley JN, Turchi JJ. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin Cancer Res. 2011;17:6973-6984.
  16. Niraparib and abiraterone acetate [prescribing information]. Raritan, NJ: Janssen Biotech, Inc.; 2023.
  17. Olaparib [prescribing information]. Gaithersburg, MD: AstraZeneca Pharmaceuticals LP; 2023.
  18. Rucaparib [prescribing information]. Boulder, CO: Clovis Oncology, Inc.; 2022.
  19. Talazoparib [prescribing information]. New York, NY: Pfizer, Inc.; 2024.
  20. Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;204:291-303.
  21. US Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools. Accessed March 19, 2024.
  22. de Bono JS, Fizazi K, Saad F, et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Presented at: European Society for Medical Oncology Congress 2019; September 27 - October 1, 2019. Abstract 5118.
  23. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443-453.
  24. Nicolosi P, Ledet E, Yang S, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5:523-528.
  25. Lang SH, Swift SL, White H, et al. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol. 2019;55:597-616.
  26. Griffiths. An Introduction to Genetic Analysis. 7th edition. W. H. Freeman; 2000.
  27. Nyberg T, Frost D, Barrowdale D, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol. 2020;77:24-35.
  28. Sokolova AO, Cheng HH. Genetic testing in prostate cancer. Curr Oncol Rep. 2020;22:5.
  29. Underhill HR, Kitzman JO, Hellwig S, et al. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12:e1006162.
  30. Cheng HH, Sokolova AO, Schaeffer EM, et al. Germline and somatic mutations in prostate cancer for the clinician. J Natl Compr Canc Netw. 2019;17:515-521.
  31. Chowdhury S, McDermott R, Piulats JM, et al. Genomic profiling of circulating tumor DNA (ctDNA) and tumor tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC). Presented at: European Society for Medical Oncology Congress 2018; October 19-23, 2018. Abstract 795PD.
  32. Zhao SG, Sperger JM, Schehr JL, et al. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. J Clin Invest. 2022;132:e161858.
  33. Scher HI, Morris MJ, Kelly WK, et al. Prostate cancer clinical trial end points: “RECIST”ing a step backwards. Clin Cancer Res. 2005;11:5223-5232.
  34. Mateo J, Seed G, Bertan C, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest. 2020;130:1743-1751.
  35. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, and pancreatic. v.3.2024. nccn.org. Accessed March 19, 2024.
  36. Isaacsson Velho P, Silberstein JL, Markowski MC, et al. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate. 2018;78:401-407.
  37. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer. v.3.2024. nccn.org. Accessed March 19, 2024.
  38. Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209:1082-1090.
  39. Russo J, Giri VN. Germline testing and genetic counselling in prostate cancer. Nat Rev Urol. 2022;19:331-343.
  40. NIH National Human Genome Research Institute. Genetic discrimination. genome.gov/about-genomics/policy-issues/Genetic-Discrimination. Accessed March 19, 2024.
  41. Casolino R, Beer PA, Chakravarty D, et al. Interpreting and integrating genomic tests results in clinical cancer care: overview and practical guidance. CA Cancer J Clin. 2024;[Epub ahead of print].
  42. Chi KN. How to read a genomic testing report. Presented at: Advanced Prostate Cancer Consensus Conference 2022; April 28-30, 2022.
  43. Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38:3763-3772.
  44. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-2102.
  45. Abida W, Campbell D, Patnaik A, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res. 2020;26:2487-2496.
  46. Abida W, Campbell D, Patnaik A, et al. Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study. Eur Urol. 2023;84:321-330.
  47. Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician's choice in metastatic prostate cancer. N Engl J Med. 2023;388:719-732.
  48. Hussain M, Mateo J, Fizazi K, et al. N Engl J Med. Survival with olaparib in metastatic castration-resistant prostate cancer. 2020;383:2345-2357.
  49. de Bono JS, Matsubara N, Penel N, et al. Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound. Presented at: 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 11-13, 2021. Abstract 126.
  50. Tung NM, Robson ME, Ventz S, et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38:4274-4282.
  51. Rudolph J, Jung K, Luger K. Inhibitors of PARP: number crunching and structure gazing. Proc Natl Acad Sci U S A. 2022;119:e2121979119.
  52. Agarwal N, Zhang T, Efstathiou E, et al. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. Eur J Cancer. 2023;192:113249.
  53. Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;29:374.
  54. Li L, Karanika S, Yang G, et al. Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10:eaam7479.
  55. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1.
  56. Saad F, Clarke NW, Oya M, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094-1108.
  57. Chi KN, Rathkopf D, Smith MR, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41:3339-3351.
  58. Chi KN, Sandhu S, Smith MR, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34:772-782.
  59. Chi KN, Rathkopf DE, Smith MR, et al. Phase 3 MAGNITUDE study: first results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Presented at: 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 17-19, 2022. Abstract 12.
  60. Chi KN, Castro E, Attard G, et al. Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: three-year update and final analysis (FA) of MAGNITUDE. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA85.
  61. Fizazi K, Azad AA, Matsubara N, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024;30:257-264.
  62. Hussain MHA, Kocherginsky M, Agarwal N, et al. BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm). Presented at: 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium; January 25-27, 2024. Abstract 19.
  63. Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389:1453-1465.
  64. Zhao Q, Ma P, Fu P, et al. Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase (PARP) inhibitors: a real-world analysis of postmarketing surveillance data. Front Pharmacol. 2022;13:912256.